Compare iShares MSCI Australia ETF (EWA) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? iShares MSCI Australia ETF trades at $28.45 (market cap $1.20B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 4.1× iShares MSCI Australia ETF's market cap, and iShares MSCI Australia ETF is more actively traded (1,742,887 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 61 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| EWA | TVTX | |
|---|---|---|
Market Cap | $1.20B | $4.88B |
Volume | 1,742,887 | 1,668,577 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $67.52 |
52-Week Low | $24.95 | $26.79 |
Typical Hold Time | 61 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA, the iShares MSCI Australia ETF, trades at $28.77, up 0.35% today, but technical indicators signal a bearish trend with moving averages and key oscillators like the 6-day RSI at 75.94 suggesting overbought conditions. The ETF tracks Australian equities, heavily weighted toward commodities and financials, with recent news highlighting institutional selling by Squarepoint Ops LLC amid broader market concerns over inflation and oil price volatility.
The outlook for EWA hinges on commodity demand and global economic trends, offering exposure to Australia's resource-driven economy but facing risks from inflation and geopolitical tensions. Analyst sentiment is mixed, with Seeking Alpha rating it a Buy targeting over 20% upside, while technical weakness and institutional selling pose near-term headwinds.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
